Compare SQNS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | XLO |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.0M | 49.8M |
| IPO Year | 2011 | 2021 |
| Metric | SQNS | XLO |
|---|---|---|
| Price | $3.06 | $8.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | $20.33 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 273.3K | 28.5K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $49.79 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.73 | $0.46 |
| 52 Week High | $10.93 | $9.25 |
| Indicator | SQNS | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 38.68 | 52.36 |
| Support Level | $2.98 | $7.47 |
| Resistance Level | $3.27 | $8.80 |
| Average True Range (ATR) | 0.34 | 0.37 |
| MACD | -0.15 | -0.05 |
| Stochastic Oscillator | 2.05 | 51.64 |
Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its offer 5G/4G chips and modules fully optimized for non-smartphone devices. The company covers applications such as smart mobility and logistics, smart utility meters, smart cities, smart industries, e-health and wellness, and smart homes to name few. The Company has one operating segment, which is the design and marketing of semiconductor components for cellular wireless systems. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.